Biologics eat 51% of drug spending despite 5% of prescriptions, but FDA's new draft guidance hopes more competition can close that gap.

Therapeutic developers are increasingly rebuilding their workflows around AI to bring drugs to patients faster.

Roche’s shares tumbled nearly 5% on news that a key pillar in the five-pronged clinical plan for the breast cancer asset ...

Ipsen telegraphed plans to acquire Epizyme and the FDA-approved Tazverik in June 2022, two years after the med’s clearance in the U.S. as both an epithelioid sarcoma and follicular lymphoma treatment.

As a world leader in the immuno-oncology field, Dr. Zihai Li has long been at the forefront of cancer immunotherapy.

persevERA is the first of two distinct Phase III studies in the first-line setting; the pionERA study of giredestrant in combination with physician’s choice of cyclin-dependent kinase (CDK)4/6 ...

A “significant number of patients” could see a cure for multiple myeloma within the next two decades, one expert told ...

A group of natural compounds attracting attention for their anti-aging potential has a dark side. New research shows how a ...

The firm received FDA feedback on the design of registrational studies of VS-7375, while it awaits new data for Avmapki Fakzynja.

A leading oncologist proposes classifying metastatic cancer by molecular alterations rather than organ origin, arguing that the shift could accelerate drug access.

Phil Low, a Purdue University scholar and entrepreneur who developed cancer therapies and founded seven companies, has died at 78.

Purdue University drug discovery scholar and faculty member, entrepreneur, and philanthropist Philip Low, whose life’s work turned laboratory discoveries into therapies ...